| Literature DB >> 32213034 |
Manuel Tufoni1, Giacomo Zaccherini1, Paolo Caraceni1, Mauro Bernardi1.
Abstract
Albumin is currently employed as a plasma expander to prevent and treat specific complications of cirrhosis with ascites, such as the prevention of paracentesis-induced circulatory dysfunction and renal dysfunction induced by spontaneous bacterial peritonitis, as well as the diagnosis and treatment of acute kidney injury and hepatorenal syndrome. Recently, evidence has shown that long-term albumin administration in patients with decompensated cirrhosis reduces mortality and incidence of complications, eases the management of ascites, is cost effective, and has a good safety profile.Entities:
Keywords: Liver cirrhosis; acute kidney injury; ascites; hepatorenal syndrome; human albumin; paracentesis; spontaneous bacterial peritonitis
Mesh:
Substances:
Year: 2020 PMID: 32213034 PMCID: PMC7268936 DOI: 10.1177/2050640620910339
Source DB: PubMed Journal: United European Gastroenterol J ISSN: 2050-6406 Impact factor: 4.623